Normalization of Polymerase Activity
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 61/705,603, filed Sep 25, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,385,087 | Normalization of Polymerase Activity In force · Medium confidence UsedRemaining | Exact Sciences Corporation | In force | Medium confidence | ||
| US 9,212,392 | Normalization of Polymerase Activity In force · High confidence | Exact Sciences Corporation | In force | High confidence | ||
| US 10,106,844 | Normalization of Polymerase Activity In force · High confidence | Exact Sciences Corporation | In force | High confidence | ||
| US 10,954,556 | Normalization of Polymerase Activity In force · High confidence | Exact Sciences Corporation | In force | High confidence | ||
| US 11,708,603 | Normalization of Polymerase Activity In force · Medium confidence | Exact Sciences Corporation | In force | Medium confidence | ||
| Application 19/030,566 | Normalization of Polymerase Activity Pending Not granted | Exact Sciences Corporation | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Exact Sciences Corporation.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.